Littérature scientifique sur le sujet « Treatment-Resistant Depression (TRD) »
Créez une référence correcte selon les styles APA, MLA, Chicago, Harvard et plusieurs autres
Consultez les listes thématiques d’articles de revues, de livres, de thèses, de rapports de conférences et d’autres sources académiques sur le sujet « Treatment-Resistant Depression (TRD) ».
À côté de chaque source dans la liste de références il y a un bouton « Ajouter à la bibliographie ». Cliquez sur ce bouton, et nous générerons automatiquement la référence bibliographique pour la source choisie selon votre style de citation préféré : APA, MLA, Harvard, Vancouver, Chicago, etc.
Vous pouvez aussi télécharger le texte intégral de la publication scolaire au format pdf et consulter son résumé en ligne lorsque ces informations sont inclues dans les métadonnées.
Articles de revues sur le sujet "Treatment-Resistant Depression (TRD)"
Gałecki, Piotr, Jerzy Samochowiec, Magdalena Mikułowska et Agata Szulc. « Treatment-Resistant Depression in Poland—Epidemiology and Treatment ». Journal of Clinical Medicine 11, no 3 (18 janvier 2022) : 480. http://dx.doi.org/10.3390/jcm11030480.
Texte intégralBrenner, Philip, Johan Reutfors, Michel Nijs et Therese M.-L. Andersson. « Excess deaths in treatment-resistant depression ». Therapeutic Advances in Psychopharmacology 11 (janvier 2021) : 204512532110065. http://dx.doi.org/10.1177/20451253211006508.
Texte intégralKasper, Siegfried, et Alan Frazer. « Editorial for Treatment-Resistant Depression (TRD) ». International Journal of Neuropsychopharmacology 22, no 2 (1 février 2019) : 83–84. http://dx.doi.org/10.1093/ijnp/pyz006.
Texte intégralBonner, Deirdre, et Robert Howard. « Treatment-Resistant Depression in the Elderly ». International Psychogeriatrics 7, S1 (octobre 1995) : 83–94. http://dx.doi.org/10.1017/s1041610295002377.
Texte intégralPETERSEN, T., J. A. GORDON, A. KANT, M. FAVA, J. F. ROSENBAUM et A. A. NIERENBERG. « Treatment resistant depression and Axis I co-morbidity ». Psychological Medicine 31, no 7 (octobre 2001) : 1223–29. http://dx.doi.org/10.1017/s0033291701004305.
Texte intégralPetersen, Timothy, George I. Papakostas, Yasmin Mahal, Wendy M. Guyker, Erin C. Beaumont, Jonathan E. Alpert, Maurizio Fava et Andrew A. Nierenberg. « Psychosocial functioning in patients with treatment resistant depression ». European Psychiatry 19, no 4 (juin 2004) : 196–201. http://dx.doi.org/10.1016/j.eurpsy.2003.11.006.
Texte intégralKolar, D. « Treatment-Resistant Depression – What is the Effective Maintenance Treatment ». European Psychiatry 65, S1 (juin 2022) : S555—S556. http://dx.doi.org/10.1192/j.eurpsy.2022.1422.
Texte intégralMillet, E., R. Icick et J. P. Lépine. « Treatment-resistant depression : From pseudo-resistance to full resistance ». European Psychiatry 26, S2 (mars 2011) : 638. http://dx.doi.org/10.1016/s0924-9338(11)72344-6.
Texte intégralRannanpää, S., H. Taipale, A. Tanskanen, M. Lähteenvuo, S. Huoponen et J. Tiihonen. « Healthcare costs and productivity losses in treatment-resistant depression in Finland ». European Psychiatry 65, S1 (juin 2022) : S268. http://dx.doi.org/10.1192/j.eurpsy.2022.686.
Texte intégralMacewan, G. William, et Ronald A. Remick. « Treatment Resistant Depression : A Clinical Perspective* ». Canadian Journal of Psychiatry 33, no 9 (décembre 1988) : 788–92. http://dx.doi.org/10.1177/070674378803300902.
Texte intégralThèses sur le sujet "Treatment-Resistant Depression (TRD)"
Cuomo, Alessandro. « "TREATMENT-RESISTANT DEPRESSION" AND USE OF INTRAVENOUS KETAMINE AND INTRANASAL ES-KETAMINE ». Doctoral thesis, Università di Siena, 2021. http://hdl.handle.net/11365/1148507.
Texte intégralFerri, Giovanni. « Study on hippocampal brain volumes in treatment resistant depression during vagal nerve stimulation (VNS) ». Doctoral thesis, Università degli studi di Padova, 2011. http://hdl.handle.net/11577/3421693.
Texte intégralPREMESSE: Modifiche nella volumetria delle strutture limbiche-paralimbiche coinvolte nella regolazione del tono dell’umore sono state descritte nella letteratura più recente sui Disturbi Depressivi Maggiori (DDM). Una diminuzione nei volumi della sostanza grigia ippocampale è uno dei possibili meccanismi coinvolti nella patogenesi della depressione [Nifosì et al. 2010]. Evidenze convergenti sembrano confermare che in corso di depressione una ridotta neurogenesi possa verificarsi in questa area e che una modulazione positiva di tale processo sia fondamentale per l’azione antidepressiva. La Neurogenesi è stimolata sia da stimoli che rafforzano la plasticità neuronale (come stimolazioni ambientali esterne, esercizio fisico, stimolazione elettrica) sia dai trattamenti antidepressivi. In studi di neuroimaging funzionale, la Stimolazione del Nervo Vago, (VNS) una metodica di recente introduzione per il trattamento della Depressione farmaco Resistente (TRD), è stata dimostrato che la sua azione antidepressiva può essere correlata con modifiche nel flusso ematico cerebrale nella corteccia limbica e prefrontale [Zobel et al 2005]. Obiettivo di questo studio è valutare se modifiche delle volumetrie in specifiche aree coinvolte nella depressione, possano essere ottenuta mediante la VNS. METODOLOGIA: E’ stato effettuato un confronto dei dati sulle modifiche di volume di specifiche regioni d’interesse in 6 pazienti con depressione farmaco resistente trattati mediante VNS (VNS Therapy System™, Cyberonics, Houston, Texas –USA) con i volumi delle stesse aree in 5 casi di TRD trattati in maniera convenzionale. Le Risonanze Magnetiche Nucleari (MRI) cerebrali sono state realizzate prima dell’impianto (t0 ) e dopo 12 mesi( t1). L’entità della depressione è stata valutata mediante scale autosomministrate (BDI ) o etero somministrate (HDRS) ogni tre mesi durante il del monitoraggio clinico. RISULTATI: Tre dei sei pazienti che hanno ricevuto la VNS hanno manifestato una buona risposta clinica (riduzione dei punteggi alle scale per la depressione > 50% dai punteggi iniziali) a tre mesi dall’inizio del trattamento. Un aumento significativo di circa il 22% e del 14% rispettivamente per ippocampo sinistro e destro è stato messo in luce dopo un anno di trattamento mediante VNS. Nessuna correlazione è stata trovata tra le principali variabili indicative dell’andamento clinico e l’aumento dei volumi cerbrali. I pazienti non responsivi alla VNS non hanno manifestato aumenti nei volumi ippocampali. I dati preliminari riscontrati in questo piccolo gruppo sembrano confermare il ruolo fondamentale del rimodellamento ippocampale come marker per la possibile risposta clinica nella TRD.
Arildsson, Mathilda. « Har ketamin effekt mot terapiresistent depression ? » Thesis, Linnéuniversitetet, Institutionen för kemi och biomedicin (KOB), 2019. http://urn.kb.se/resolve?urn=urn:nbn:se:lnu:diva-81676.
Texte intégralDepression is a syndrome characterized by depressed mood, loss of interest and energy, feelings of guilt or worthlessness and thoughts of death and suicide. Over 300 million people suffer from depression and it is one of the leading causes of disability in the world. Today’s treatment for depression includes psychological treatment as well as pharmacological treatment. While there are many antidepressant drugs, it can take up to weeks or even months before a clinical effect in the severity of the depression can be noticed. In addition, one third of the patients do not achieve remission. These patients, after treatment with two antidepressant medications given at adequate doses for an adequate duration, are considered to have treatment-resistant depression (TRD). Ketamine is a drug long used for its anesthetic and analgesic effects, but it is also known as a party-drug that can cause out-of-body experience. However, it has also been found that a single-dose ketamine may give people with TRD a rapid antidepressant effect, within 24 hours. In contrast to current antidepressant medications which primarily acts on the monoaminergic system, ketamine instead acts on the glutamatergic system. The aim of this study was to evaluate if ketamine has an effect on people suffering from TRD. This study is a literature review where five randomized controlled trials on the effect of ketamine in patients with TRD have been analyzed. Four studies evaluated the effect of intravenous ketamine where one of them used a varied dose frequency and one of them used esketamine in various doses. The fifth study evaluated the effect of intranasal administration of ketamine. All studies were found in the database PubMed. The overall result shows that ketamine has an effect on TRD. After 24 hours all the studies showed a significant improvement in the severity of the depression with ketamine treatment compared to placebo (p <0.05). Ketamine treatment resulted in a 7-16 points larger reduction in depressive symptoms on the scales used compared to placebo. This represents on average a change from severe/moderately severe depression to mild depression. There was also a significant difference in response (at least 50 % reduction in points from baseline on the scale used) after 24 hours with ketamine treatment compared to placebo (p <0.05). The proportion of ketamine treated patients with response varied between 44-71 % compared to 0-6 % for placebo and 28 % for active placebo (midazolam). Even though ketamine seems to have an effect on patients with TRD there is still limited knowledge of how the antidepressant effect shall be maintained and the safety of long-term use. Further studies are needed to determine if ketamine will be an option in future antidepressant treatment against TRD.
Livres sur le sujet "Treatment-Resistant Depression (TRD)"
Lam, Raymond W. Depression. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780198804147.001.0001.
Texte intégralHowland, Robert H. Multidisciplinary Treatments and Medications for Depressive Disorders and Comorbidity. Sous la direction de C. Steven Richards et Michael W. O'Hara. Oxford University Press, 2014. http://dx.doi.org/10.1093/oxfordhb/9780199797004.013.008.
Texte intégralGoodman, Wayne K., et Mark S. George. Neuromodulation and Psychiatric Disorders. Sous la direction de Dennis S. Charney, Eric J. Nestler, Pamela Sklar et Joseph D. Buxbaum. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780190681425.003.0010.
Texte intégralChapitres de livres sur le sujet "Treatment-Resistant Depression (TRD)"
Selek, Salih, et Jair C. Soares. « Neurobiology and Evidence-Based Review on Novel Therapeutic Strategy for Treatment-Resistant Depression (TRD) ». Dans Understanding Depression, 269–75. Singapore : Springer Singapore, 2017. http://dx.doi.org/10.1007/978-981-10-6577-4_19.
Texte intégral« Depression : Treatment-Resistant (TRD) ». Dans The APRN and PA’s Complete Guide to Prescribing Drug Therapy. New York, NY : Springer Publishing Company, 2019. http://dx.doi.org/10.1891/9780826179357.0097b.
Texte intégralLam, Raymond W. « Special populations ». Dans Depression, 95–112. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780198804147.003.0010.
Texte intégralHoltzheimer, Paul E., et Helen Mayberg. « Subcallosal cingulate deep brain stimulation for treatment-resistant depression ». Dans Landmark Papers in Psychiatry, sous la direction de Elizabeth Ryznar, Aderonke B. Pederson, Mark A. Reinecke et John G. Csernansky, 311–26. Oxford University Press, 2020. http://dx.doi.org/10.1093/med/9780198836506.003.0019.
Texte intégralActes de conférences sur le sujet "Treatment-Resistant Depression (TRD)"
Zöllner, R., M. Bopp, P. Dietsche, H. Rekate, B. Dietsche, A. Krug, B. Hanewald, O. Steinsträter, J. Sommer et M. Zavorotnyy. « Structural and metabolic changes in the anterior cingulate cortex (ACC) after treatment with repetitive transcranial magnetic stimulation (rTMS) in patients with treatment-resistant unipolar depression (TRD) ». Dans Abstracts of the 30th Symposium of the AGNP. Georg Thieme Verlag KG, 2017. http://dx.doi.org/10.1055/s-0037-1606408.
Texte intégralWadkar, Abhijeet, Prithvi K. Jupalli et Samuel F. Asokanthan. « Simulation of Magnetic Field Induced Current for Magnetic Seizure Therapy ». Dans ASME 2017 International Mechanical Engineering Congress and Exposition. American Society of Mechanical Engineers, 2017. http://dx.doi.org/10.1115/imece2017-72671.
Texte intégral